Literature DB >> 28706905

A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.

Isabelle Opitz1, Walter Weder1.   

Abstract

Multimodality treatment including macroscopic complete resection (MCR) is currently the most effective therapy for patients with malignant pleural mesothelioma (MPM). However, the allocation to one of the possible combinations has to be discussed individually since various factors influence the decision making process. In the past years, relevant new information about the disease and the outcome of different treatment modalities have been generated, which allows a more individual allocation to the best treatment. For many years extrapleural pneumonectomy (EPP)-the most aggressive procedure to achieve a MCR-was the first choice in combination with adjuvant or neo-adjuvant chemotherapy and radiation therapy for all patients except those with minimal disease. However, mortality and morbidity of an EPP and the fact, that even with the most radical procedure only MCR and not a complete resection can be achieved, led to shift towards pleurectomy/decortication in most of the centers. But also today, EPP is still a valuable option in selected cases and the entire treatment concept requires a nuanced view, which will be discussed in this review.

Entities:  

Keywords:  Extrapleural pneumonectomy (EPP); malignant pleural mesothelioma (MPM); multimodality treatment; outcome

Year:  2017        PMID: 28706905      PMCID: PMC5497104          DOI: 10.21037/atm.2017.03.88

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  32 in total

1.  Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.

Authors:  Ottavio Rena; Caterina Casadio
Journal:  Lung Cancer       Date:  2012-01-11       Impact factor: 5.705

2.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

3.  Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?

Authors:  Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).

Authors:  A Brunelli; A Charloux; C T Bolliger; G Rocco; J-P Sculier; G Varela; M Licker; M K Ferguson; C Faivre-Finn; R M Huber; E M Clini; T Win; D De Ruysscher; L Goldman
Journal:  Eur Respir J       Date:  2009-07       Impact factor: 16.671

5.  Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.

Authors:  Apostolos Nakas; David Waller
Journal:  Eur J Cardiothorac Surg       Date:  2014-01-30       Impact factor: 4.191

6.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

7.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

Authors:  David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

8.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Authors:  Rolf A Stahel; Oliver Riesterer; Alexandros Xyrafas; Isabelle Opitz; Michael Beyeler; Adrian Ochsenbein; Martin Früh; Richard Cathomas; Kristiaan Nackaerts; Solange Peters; Christoph Mamot; Alfred Zippelius; Carlo Mordasini; Clemens B Caspar; Katrin Eckhardt; Ralph A Schmid; Daniel M Aebersold; Oliver Gautschi; Wolfgang Nagel; Michael Töpfer; Jerome Krayenbuehl; Karin Ribi; Ilja Ciernik; Walter Weder
Journal:  Lancet Oncol       Date:  2015-11-02       Impact factor: 41.316

9.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

10.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

View more
  1 in total

Review 1.  Extrapleural pneumonectomy: still indicated?

Authors:  Andreas Domen; Lawek Berzenji; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2018-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.